Table 3. Detection rate (‰) for cancer and for significant neoplasiaa by screening strategy and difference with the reference strategyb.
|
Detection rate × 1000 screened subjects
|
|||
|---|---|---|---|
|
2–day strategy
|
|||
| Cutoff | 1-day strategy | (at least one sample with positive result) | (both samples with positive results) |
| Cancer | |||
| ⩾80 ng ml−1 | 2.9 | 3.4 | 2.3 |
| +0.1 (−0.9 to 1.1) | +0.6 (−0.5 to 1.7) | −0.5 (−1.5 to 0.5) | |
| ⩾100 ng ml−1 | 2.8b | 3.4 | 2.1 |
| (reference) | +0.6 (−0.5 to 1.7) | −0.6 (−1.6 to 0.3) | |
| ⩾120 ng ml−1 | 2.7 | 3.3 | 2.1 |
| −0.1 (−1.1 to 1.0) | +0.5 (−0.6 to 1.5) | −0.6 (−1.6 to 0.3) | |
| Significant neoplasia | |||
| ⩾80 ng ml−1 | 20.7 | 25.9c | 14.6c |
| +2.3 (−0.4 to 5.0) | +7.5 (4.7–10.4) | −3.8 (−6.3 to −1.3) | |
| ⩾100 ng ml−1 | 18.4b | 23.1c | 12.8c |
| (reference) | +4.7 (1.9–7.4) | −5.6 (−8.0 to −3.2) | |
| ⩾120 ng ml−1 | 17.3 | 21.7d | 12.1c |
| −1.1 (−3.6 to 1.5) | +3.3 (0.6–6.0) | −6.3 (−8.6 to −3.9) | |
Statistical comparison of strategies (with Bonferroni correction for multitesting).
95% CI (confidence interval) of difference is given in brackets.
a
Significant neoplasia: cancer+advanced adenoma (any adenoma larger than 9 mm, and/or with a villous histological component higher than 20%, and/or with severe dysplasia).
b
Reference strategy: 1-day and cutoff ⩾100 ng ml−1.
c
Differences among strategy and the reference strategy were statistically significant at P<0.00625 (threshold for significance after Bonferroni correction).
d
Non-significant at P<0.00625 (P=0.0168).